TABLE 2.
Absolute risk reductions and numbers of patients needed to treat or harm by eGFR subgroups at 3 years of follow‐up
| Outcome | eGFR subgroup at baseline (mL/min/1.73m2) | Number of patients with an event during the trial | ARR (95% CI) | NNT (95% CI) | NNH |
|---|---|---|---|---|---|
| First MACE | ≥90 | 375 | 1.1 (−0.7; 2.9) | 92 (35; ∞) | — |
| 60 to <90 | 532 | 0.1 (−1.6; 1.9) | 868 (54; ∞) | — | |
| 45 to <60 | 208 | 5.1 (1.7; 8.5) | 20 (12; 58) | — | |
| 30 to <45 | 136 | 6.5 (1.0; 11.9) | 15 (8; 97) | — | |
| <30 | 51 | 2.0 (−8.1; 12.2) | 49 (8; ∞) | — | |
| CV death | ≥90 | 110 | 0.8 (−0.1; 1.7) | 119 (58; ∞) | — |
| 60 to <90 | 198 | 0.3 (−0.7; 1.3) | 337 (75; ∞) | — | |
| 45 to <60 | 84 | 1.5 (−0.5; 3.5) | 67 (28; ∞) | — | |
| 30 to <45 | 77 | 4.3 (0.2; 8.5) | 23 (12; 496) | — | |
| <30 | 28 | 5.8 (−2.4; 13.9) | 17 (7; ∞) | — | |
| All‐cause death | ≥90 | 179 | 1.2 (0.1; 2.3) | 85 (44; 1230) | — |
| 60 to <90 | 327 | −0.0 (−1.3; 1.2) | — | 3861 | |
| 45 to <60 | 148 | 1.9 (−0.7; 4.4) | 54 (23; ∞) | — | |
| 30 to <45 | 121 | 5.8 (1.2; 10.3) | 17 (10; 87) | — | |
| <30 | 53 | 3.8 (−5.8; 13.5) | 26 (7; ∞) | — | |
| Renal outcome a | ≥90 | 22 | 0.1 (−0.2; 0.5) | 699 (206; ∞) | — |
| 60 to <90 | 50 | 0.0 (−0.3; 0.4) | 2759 (248; ∞) | — | |
| 45 to <60 | 43 | 1.1 (−0.6; 2.8) | 91 (36; ∞) | — | |
| 30 to <45 | 62 | 2.3 (−1.5; 6.2) | 43 (16; ∞) | — | |
| <30 | 66 | 1.0 (−10.4; 12.4) | 102 (8; ∞) | — | |
| Hospitalization for heart failure | ≥90 | 104 | 0.3 (−0.7; 1.2) | 382 (84; ∞) | — |
| 60 to <90 | 178 | 0.0 (−1.1; 1.1) | — | — | |
| 45 to <60 | 87 | 2.7 (0.4; 4.9) | 37 (20; 235) | — | |
| 30 to <45 | 72 | 3.7 (−0.3; 7.6) | 27 (13; ∞) | — | |
| <30 | 25 | −4.3 (−10.8; 2.3) | — | 24 |
Persistent doubling of serum creatinine and eGFR ≤45 mL/min/1.73m2, the need for continuous renal replacement therapy (in the absence of an acute reversible cause; ESRD) or death from renal disease. NNT presented where the treatment difference favoured liraglutide; NNH presented where the treatment difference favoured placebo. CIs were calculated on the risk difference scale and the reciprocals were then generated. The infinity notation has been used where the CI contains zero or negative values. No 95% CIs are available for NNH (negative NNT).
Abbreviations: ARR, absolute risk reduction; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end‐stage renal disease; MACE, major adverse cardiovascular events; NNH, numbers needed to harm; NNT, numbers needed to treat.